3.25
+0.15(+4.84%)
Currency In USD
| Previous Close | 3.1 |
| Open | 3.05 |
| Day High | 3.29 |
| Day Low | 3.01 |
| 52-Week High | 3.44 |
| 52-Week Low | 1.35 |
| Volume | 5.44M |
| Average Volume | 4.09M |
| Market Cap | 640.36M |
| PE | -4.85 |
| EPS | -0.67 |
| Moving Average 50 Days | 2.13 |
| Moving Average 200 Days | 2.22 |
| Change | 0.15 |
If you invested $1000 in Esperion Therapeutics, Inc. (ESPR) 10 years ago, it would be worth $90.38 as of December 04, 2024 at a share price of $3.25. Whereas If you bought $1000 worth of Esperion Therapeutics, Inc. (ESPR) shares 5 years ago, it would be worth $63 as of December 04, 2024 at a share price of $3.25.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk
GlobeNewswire Inc.
Dec 02, 2024 1:00 PM GMT
ANN ARBOR, Mich., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has filed New Drug Submissions (NDSs) to Health Canada for NEXLETOL and NEXLIZET, once-daily, accessible, oral non-statin medications that reduce lo
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia
GlobeNewswire Inc.
Nov 26, 2024 1:00 PM GMT
ANN ARBOR, Mich., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka) has submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare for the manu
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 21, 2024 1:00 PM GMT
ANN ARBOR, Mich., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024, at 12:30 p.m. ET